• November 16 , 2009
    Boehringer Ingelheim Announces Pivotal Phase III Data of Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder
  • November 10 , 2009
    Budding Videographers Vividly Portray Life with Diabetes to Mark World Diabetes Day
  • October 26, 2009
    Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business from Pfizer
  • October 19, 2009
    FDA Approves New Use for Micardis® in Cardiovascular Risk Reduction and Twynsta® as New Combination Treatment for High Blood Pressure
  • October 6, 2009
    Boehringer Ingelheim Launches Co-Pay Rebate Program for Viramune
  • September 29, 2009
    Boehringer Ingelheim’s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III clinical program for linagliptin
  • September 24, 2009
    Making Sense of Diabetes Video Contest Asks "What Does Diabetes Taste, Smell or Sound Like to You?"
  • September 21, 2009
    Boehringer Ingelheim Animal Health Enters into Agreement to Acquire Certain Assets of Fort Dodge Animal Health from Pfizer
  • September 15, 2009
    Boehringer Ingelheim Earns Top Marks in 2010 Corporate Equality Index
  • August 30, 2009
    RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients
  • August 25, 2009
    Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
  • August 3, 2009
    Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
  • June 6, 2009
    Boehringer Ingelheim Unveils Diabetes Pipeline
  • May 28, 2009
    AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
  • May 18, 2009
    New Research Finds Recession Has Greater Impact on Health of Parents Than Children
  • May 14, 2009
    Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
  • April 29, 2009
    New Studies on Once-daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
  • April 17, 2009
    New Program Educates About Serious Warning Sign for Stroke
  • March 31, 2009
    Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
  • March 20, 2009
    Final Patient Completes Treatment In Boehringer Ingelheim’s RE-LY® Study, the Largest Atrial Fibrillation Outcomes Trial To Date
  • March 3, 2009
    New Five-Question Diagnostic Tool Helps Health Care Professionals Accurately Diagnose Hypoactive Sexual Desire Disorder (HSDD) in Women